Results 71 to 80 of about 6,306 (210)

A tutorial on pharmacometric Markov models

CPT: Pharmacometrics & Systems Pharmacology
AbstractThe Markov chain is a stochastic process in which the future value of a variable is conditionally independent of the past, given its present value. Data with Markovian features are characterized by: frequent observations relative to the expected changes in values, many consecutive same‐category or similar‐value observations at the individual ...
Qing Xi Ooi, Elodie Plan, Martin Bergstrand   +2 more
openaire   +2 more sources

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2672-2681, August 2026.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma

npj Systems Biology and Applications
Elranatamab, an approved bispecific antibody (BsAb) for relapsed/refractory multiple myeloma, forms an immune synapse between the T-cell CD3 marker and B-cell maturation antigen (BCMA) on myeloma cells. Circulating soluble BCMA (sBCMA) is associated with
Kamrine E. Poels, Mohamed Elmeliegy, Jennifer Hibma, Diane Wang, Cynthia J. Musante, Blerta Shtylla   +5 more
doaj   +1 more source

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin

Clinical and Translational Science, 2020
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetoclax on ...
Ali A. Alhadab, Ahmed Hamed Salem, Kevin J. Freise   +2 more
doaj   +1 more source

CPT: Pharmacometrics and Systems Pharmacology

CPT: Pharmacometrics & Systems Pharmacology, 2012
Welcome to the first issue of CPT: Pharmacometrics and Systems Pharmacology (CPT:PSP), a new journal from the American Society for Clinical Pharmacology and Therapeutics. CPT:PSP is a cross‐disciplinary journal devoted to publishing advances in quantitative, model‐based approaches as applied in pharmacology, (patho)physiology, and disease to aid the ...
openaire   +2 more sources

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2682-2692, August 2026.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup, Michel Tod, Laurent Bourguignon   +2 more
wiley   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2764-2776, August 2026.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2885-2898, August 2026.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation

CPT: Pharmacometrics & Systems Pharmacology
Physiologically Based Pharmacokinetic (PBPK) modeling is a powerful tool in drug development that integrates drug‐specific information with physiological parameters to predict drug concentrations.
Donato Teutonico, David Marchionni, Marc Lavielle, Laurent Nguyen   +3 more
doaj   +1 more source

Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Clinical Pharmacology in Drug Development, Volume 15, Issue 8, August 2026.
Abstract Dostarlimab in combination with carboplatin–paclitaxel was approved for primary advanced or recurrent endometrial cancer (pA/rEC). The first interim analysis (IA1) of RUBY Part 1 (NCT03981796) showed no significant exposure–response (ER) relationship for progression‐free survival or for the five most common dostarlimab‐related adverse events ...
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Angela Jain, Oskar Alskär, Oleksandr Zub, Mark S. Shahin, Anthoula Koliadi, Bhavana Pothuri, Thomas Krivak, Mikalai Pishchyk, Yakir Segev, Floor J. Backes, Christine Gennigens, Sara Bouberhan, Stefan Zajic, Murad Melhem, Joseph Buscema   +17 more
wiley   +1 more source